PTS, Inc. Announces New IT Service Contract! Stock Watch On PTSH, SNY, MRK and LLY.

Nov. 9, 2010 - PRLog -- PTS, Inc. (OTC.BB:PTSH) announced today that through its ThinLine division it has signed a 3 year IT Services deal with United Power.

United Power is acknowledged experts on the resale of products especially suited for medium voltage power distribution, in addition to providing a wide portfolio of products for other aspect of the electrical utility business. United Power has been serving electrical utility Customers within Georgia continuously since 1976. They have developed a reputation for customer sensitivity, fair dealing and exceptional quality during this time.

United Power required an IT solution that would allow them to contact one source for all of their IT needs.

"United Power is a well-established and quality company that has been a leader in their field for decades" stated Raj Kalra CEO of PTS. "They were looking for a one stop shop that would be able to handle their IT, disaster recovery and hardware needs without making more than one phone call. ThinLine's managed IT solution was designed for this task. We look forward to working with the team at United Power and I am always excited to add a quality client to our growing portfolio of managed It customers," added Raj Kalra.

*******************************************

Eli Lilly & Co.  announced on Monday November 8, 2010 that it has signed a definitive merger agreement to acquire Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases. Avid’s lead program in development is florbetapir F 18 (18F-AV-45), a molecular imaging agent under investigation for detecting the presence of amyloid plaque in the brain. Beta-amyloid plaque is a defining pathology of Alzheimer’s disease.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 17 other countries.

*******************************************

Merck & Co., Inc.  reported on Saturday October 30, 2010 that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment (treatment-naïve; HCV SPRINT-2) for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies. The results for the primary endpoints of these studies, which were first reported in a news release in August 2010, and a broad range of further data analyses from these studies are being presented in oral and poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Merck & Co., Inc. is a global health care company that delivers health solutions through its medicines, vaccines, biologic therapies, and consumer and animal products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis.

*******************************************

Sanofi-Aventis SA (ADR)  announced on Monday November 8, 2010 that it has sent a letter to Genzyme Corporation requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme’s Schedule 14D-9. Sanofi-aventis’ letter also notes that it is encouraged by Genzyme’s decision to “probe and evaluate alternatives” including contacting third parties but observes that sanofi-aventis has not been contacted by Genzyme or its advisors. Sanofi-aventis continues to remain interested in working with Genzyme on a constructive basis and is committed to a mutually agreeable transaction.

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. The Company’s business includes two main activities: pharmaceuticals and human vaccines through sanofi pasteur. The Company is also present in animal health products through Merial Limited.

****************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for PTS Inc.(PTSH.OB)